retatrutide trial weight loss The numbers from Lilly's Phase 3 dropped this week and I haven't been able to stop thinking about them. Not only as a doctor but as a long-term GLP-1 user Retatrutide: A Promising Option for

All trials revealed cardiovascular safety by establishing non-inferiority

WADA is expected to rule by late 2026 or 2027 on whether to formally prohibit GLP-1 receptor agonists ahead of the Los Angeles 2028 Olympic Games

With tirzepatide, constipation rates ranged from 6-11% across different dosing groups in the SURMOUNT trials

This virtual doctor visit allows you to schedule appointments and receive ongoing care from the comfort of your own home

National High Level Hospital Clinical Research Funding [grant numbers 2022-PUMCH-C-019, 2022-PUMCH-B-121]

Injectable GLP-1 medications are peptide-based drugs administered via subcutaneous injection, bypassing the gastrointestinal tract for absorption